hero image

CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

October 8, 2014 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Second paragraph, first sentence of release dated September 25, 2014 should read: Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. (instead of Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 9:00 am ET.).

The corrected release reads:

BIOGEN IDEC TO REPORT THIRD QUARTER 2014 FINANCIAL RESULTS ON OCTOBER 22, 2014

Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2014 financial results on Wednesday, October 22, 2014, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to the investor relations section of Biogen Idec’s website at www.biogenidec.com. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

 

Biogen Idec
Karen Jewell, 781-464-2442
Investor Relations

 

 

thumb
May 16, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of

thumb
May 14, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the